Analysts Set Expectations for Intercept Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) – Equities researchers at Jefferies Financial Group issued their FY2024 earnings estimates for shares of Intercept Pharmaceuticals in a research note issued to investors on Sunday, January 22nd. Jefferies Financial Group analyst M. Yee anticipates that the biopharmaceutical company will post earnings per share of ($5.03) for the year. The consensus estimate for Intercept Pharmaceuticals’ current full-year earnings is ($4.63) per share.

Intercept Pharmaceuticals (NASDAQ:ICPTGet Rating) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing the consensus estimate of $5.11 by ($8.15). The business had revenue of $77.59 million for the quarter, compared to analysts’ expectations of $75.60 million.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird decreased their price target on shares of Intercept Pharmaceuticals from $52.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, October 3rd. HC Wainwright decreased their price target on shares of Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, November 16th. Raymond James reduced their price objective on shares of Intercept Pharmaceuticals from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Piper Sandler reduced their price objective on shares of Intercept Pharmaceuticals from $82.00 to $49.00 in a research note on Friday, September 30th. Finally, StockNews.com upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 3rd. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Intercept Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $25.80.

Intercept Pharmaceuticals Trading Up 1.9 %

Shares of ICPT stock opened at $16.22 on Tuesday. The company has a 50 day moving average of $14.34 and a 200-day moving average of $15.12. The company has a quick ratio of 2.46, a current ratio of 2.46 and a debt-to-equity ratio of 2.07. Intercept Pharmaceuticals has a 12-month low of $10.81 and a 12-month high of $21.25. The firm has a market cap of $671.78 million, a P/E ratio of 2.83 and a beta of 1.18.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Amalgamated Bank bought a new position in Intercept Pharmaceuticals in the 1st quarter valued at $66,000. Great West Life Assurance Co. Can purchased a new position in shares of Intercept Pharmaceuticals in the third quarter valued at about $58,000. Point72 Hong Kong Ltd purchased a new position in shares of Intercept Pharmaceuticals in the third quarter valued at about $59,000. Fox Run Management L.L.C. purchased a new position in shares of Intercept Pharmaceuticals in the second quarter valued at about $155,000. Finally, Clear Creek Financial Management LLC purchased a new position in shares of Intercept Pharmaceuticals in the second quarter valued at about $176,000. 81.09% of the stock is owned by institutional investors.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Featured Articles

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.